Tian Zhang: Meet the Experts of VIRO 2025

The Global Voices in Renal Oncology (VIRO) Virtual Congress, organized by OncoDaily, will be held on September 11–12, 2025. Chaired by Dr. Rana R. McKay with co-chair Dr. Yüksel Ürün, this year’s program will feature around 50 leading experts in renal oncology from across the globe, sharing cutting-edge updates and future perspectives.

• The congress is free to attend.
• Register via the link.

Co-Chair of VIRO

Images

Name

Rana McKay Professor of Medicine and Urology at UC San Diego Health Co-leader of the GU Oncology Program at Moores Cancer Center As Co-Chair of VIRO, Dr. Rana McKay (University of California, San Diego) opened the congress with her talk on  “Future Directions: Emerging Agents and Combinations.” She emphasized the momentum in renal cell carcinoma (RCC) research, highlighting how novel immunotherapies, targeted drugs, and rational combination strategies are reshaping patient care. Dr. McKay underscored the importance of personalized, biomarker-driven approaches and global collaboration, aiming to optimize survival and quality of life worldwide.

Spotlight on Tian Zhang

Dr. Zhang is an Associate Professor in the Department of Internal Medicine at UT Southwestern Medical Center and serves as Associate Director of Clinical Research at the Simmons Comprehensive Cancer Center.

At the Global Voices in Renal Oncology (VIRO) Virtual Congress 2025, Dr. Zhang will present on “Current Standard of Care: IO/IO and IO/TKI Combinations.” Her presentation will cover:

• The development and clinical implementation of immune-oncology (IO) combinations in renal cell carcinoma.
• The comparative efficacy and safety of IO/IO versus IO/TKI treatment regimens.
• Biomarker-driven patient selection and personalized therapeutic strategies.
• Insights from ongoing clinical trials and future directions in immunotherapy for advanced RCC.

Dr. Zhang combines a strong clinical trial leadership role with translational research expertise, contributing to the advancement of personalized immunotherapy approaches in kidney cancer treatment.

Global Voices in Renal Oncology (VIRO) 2025